GlassScriptPhysician profile
James D Pride
NPI 1831138528
$6,638.81
in general payments reported to CMS, 2019-2025
36 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $802 · 2021: $1,153 · 2022: $1,262 · 2023: $940 · 2024: $1,088 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,681.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,079.43 | 2019-2025 | |
| Amgen INC. | $679.50 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $616.83 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $380.84 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $264.85 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $199.66 | 2020-2024 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $183.40 | 2021-2023 | |
| Lilly USA, LLC | $178.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $104.20 | 2020-2023 | Eliquis |
| Neuronetics, INC. | $101.16 | 2020-2023 | Neurostar Tms Therapy System |
| Janssen Pharmaceuticals, INC | $97.86 | 2019-2024 | Spravato |
| Jazz Pharmaceuticals INC. | $96.69 | 2021 | |
| Janssen Biotech, INC. | $85.27 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.12 | 2020-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.